Overall survival of the following four prognostic subcategories of AML aggregated according to cytogenetics: core binding factor (CBF) abnormalities; normal karyotype (CN); non-CBF abnormalities, but MK^– (MK–); and non-CBF abnormalities, but MK⁺ (MK+).